Healthtech funding in 2020
European Healthtech startup funding raised during 2020.
In 2020, 490 European Healthtech companies closed 518 funding rounds and raised €6.1B in equity funding (excluding debt and grants). Debt rounds added €65M. UK led by capital raised, and Novo Holdings was the most active investor. Data as of 18 Nov 2026.
Equity funding
€6.1B
excl. debt & grants · +€65M debt
Funding rounds
518
Companies
490
Top country
UK
Healthtech: last three years
change vs the year beforeRank among sectors
#4
9.5% of sector funding
Debt financing
€65M
1.1% of total
Top-10 round share
19.5%
of disclosed capital
Rounds ≥ €100M
5
Funding by month
€ raised vs rounds, by monthHealthtech — funding by month, 2020 — interactive chart.
Data table
| Funding | Rounds | |
|---|---|---|
| Jan | €347M | 54 |
| Feb | €365M | 37 |
| Mar | €164M | 18 |
| Apr | €533M | 39 |
| May | €412M | 35 |
| Jun | €612M | 20 |
| Jul | €858M | 60 |
| Aug | €365M | 40 |
| Sep | €865M | 64 |
| Oct | €776M | 60 |
| Nov | €545M | 51 |
| Dec | €322M | 40 |
Top countries
by € raisedHealthtech — top countries by capital, 2020 — interactive chart.
Data table
| Healthtech — top countries by capital, 2020 | |
|---|---|
| UK | €1.4B |
| Israel | €1.0B |
| Switzerland | €704M |
| Germany | €701M |
| France | €679M |
| Sweden | €409M |
| Netherlands | €297M |
| Spain | €253M |
Stage mix
by € raisedHealthtech — stage mix, 2020 — interactive chart.
Data table
| Healthtech — stage mix, 2020 | |
|---|---|
| Other | €1.9B |
| Series C | €1.1B |
| Series B | €1.0B |
| Series A | €908M |
| Series D+ | €472M |
| Early VC | €387M |
| Seed | €257M |
| Growth/Late | €93M |
| Debt | €65M |
| Grant | €27M |
| Crowdfunding | €8.6M |
| Pre-Seed | €7.7M |
Exits & M&A
37 Acquisition · 2 IPO · 1 Buyout43 exits · €2.5B disclosed.
| MYR GmbH | Acquisition | Oct 2020 | €1.1B |
| Polyplus-Transfection | Acquisition | Feb 2020 | €460M |
| Galecto | Acquisition | Jan 2020 | €398M |
| MaSTherCell | Acquisition | Feb 2020 | €285M |
| Nanox Imaging | IPO | Aug 2020 | €140M |
| Fiagon | Acquisition | Sep 2020 | €60M |
Largest equity rounds
by disclosed amount, 2020| Company | Stage | Date | Amount |
|---|---|---|---|
| CureVac | Early VC | Jun 2020 | €300M |
| Kry | Series C | Jul 2020 | €140M |
| Oxford Nanopore Technologies | Other | Apr 2020 | €124M |
| Freeline Therapeutics | Series C | Jul 2020 | €107M |
| Atai Life Sciences | Series C | Nov 2020 | €105M |
| Sophia Genetics | Series D+ | Oct 2020 | €94M |
| Vectivbio | Other | Oct 2020 | €94M |
| Neogene Therapeutics | Other | Sep 2020 | €93M |
| Compass Pathways | Series B | Apr 2020 | €74M |
| Freeline Therapeutics | Series C | Jul 2020 | €71M |
Largest debt rounds
debt financing, 2020; not in the equity total| Company | Stage | Date | Amount |
|---|---|---|---|
| Cycle Pharmaceuticals | Debt | Sep 2020 | €21M |
| Kerecis | Debt | Aug 2020 | €18M |
| Scope Fluidics | Debt | Sep 2020 | €10M |
| Rheon Medical | Debt | Dec 2020 | €5.2M |
| Doctorly | Debt | Nov 2020 | €4.7M |
Top investors
most active in 2020, by deal count- Novo Holdings6 deals
- Bpifrance5 deals
- High-Tech Gründerfonds (HTGF)5 deals
- IDInvest Partners4 deals
- Kurma Partners4 deals
- Mercia Asset Management4 deals
- Wellington Partners4 deals
- 4FO Ventures3 deals
- Amadeus Capital Partners3 deals
- Business Finland3 deals
Source: Tech.eu Funding Explorer · data as of 18 Nov 2026 · licence CC BY 4.0 · Methodology